Clinical benefit of measurement of advanced glycogen endproduct level in type 2 diabetes

Clinical benefit of measurement of advanced glycogen endproduct level in type 2 diabetes - Clinical benefit of measurement of advanced glycogen endproduct level in type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015966

Enrollment

200

Registered

2014-12-16

Start date

2014-12-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We will recruited 200 patients with type 2 diabetes who were hospitalized for glycemic control in Kumamoto University Hospital.

Exclusion criteria

Exclusion criteria: 1. Patients with infectious disease 2. Patients with acute/chronic inflammatory disease 3. Patients with cancer 4. Patients with acute cerebrovascular disease 5. Patients with severe hepatic disease 6. Patients with severe respiratory 7. Patients with mental disorder 8. Patients decided from attended doctors not to be recruited in the study

Design outcomes

Primary

Measure	Time frame
Correlation between serum level of several AGE constructs, including N-(carboxymethyl)lysine(CML), N-(carboxyethyl)lysine(CEL), S-(2-Succinyl)cysteine(2SC), Carboxymethyl-arginine(CMA), Carboxyethyl-arginine(CEA), Methylglyoxal-Imidazolone (MG-Imidazolone), Glucoselisine (GL), N-(5-hydro-5-methyl-4-imidazolon-2-yl) ornithine (MG-H1), and other experimental markers for macro- and micro-angiopathy (leukocyte counts, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, total protein, serum albumin, serum creatinin, BUN, UA, AST, ALT, LDH, CHE, ALP, g-GTP, total bilirubin, creatin kinase, fasting glucose level, fasting serum insulin level, HbA1c, hs-CRP, systatin-C, urinaly albumin level, urinaly creatinin, urinaly L-FABP, mean- and max-IMT, baPWV, TNFa, IL-1b, IL-6, adiponectin, sICAM-1, E-serectin, endothelin-1, mean- and MAX-IMT, baPWV, degree of retinopathy, degree of neuropathy and degree of nephropathy ). We also investigate correlation between amounts of AGE constructs and degree of autofluorescence by irradiation of light. Moreover, we investigate correlation between amounts of AGE constructs and the presence of micro- and macro-vascular complications.	—

Measure

Time frame

Correlation between serum level of several AGE constructs, including N-(carboxymethyl)lysine(CML), N-(carboxyethyl)lysine(CEL), S-(2-Succinyl)cysteine(2SC), Carboxymethyl-arginine(CMA), Carboxyethyl-arginine(CEA), Methylglyoxal-Imidazolone (MG-Imidazolone), Glucoselisine (GL), N-(5-hydro-5-methyl-4-imidazolon-2-yl) ornithine (MG-H1), and other experimental markers for macro- and micro-angiopathy (leukocyte counts, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, total protein, serum albumin, serum creatinin, BUN, UA, AST, ALT, LDH, CHE, ALP, g-GTP, total bilirubin, creatin kinase, fasting glucose level, fasting serum insulin level, HbA1c, hs-CRP, systatin-C, urinaly albumin level, urinaly creatinin, urinaly L-FABP, mean- and max-IMT, baPWV, TNFa, IL-1b, IL-6, adiponectin, sICAM-1, E-serectin, endothelin-1, mean- and MAX-IMT, baPWV, degree of retinopathy, degree of neuropathy and degree of nephropathy ). We also investigate correlation between amounts of AGE constructs and degree of autofluorescence by irradiation of light. Moreover, we investigate correlation between amounts of AGE constructs and the presence of micro- and macro-vascular complications.

—

Countries

Japan

Contacts

Public ContactTakeshi Matsumura

Faculty of life sciences, Kumamoto University Department of Metabolic Medicine

takeshim@gpo.kumamoto-u.ac.jp096-373-5169

Outcome results